arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

RIGEL PHARMACEUTICALS INC

RIGL
$45.27 ▼ -6.03 (-11.75%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
84
Health
Excellent
Bullish
auto_awesome

Analytical Summary

RIGEL PHARMACEUTICALS INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $839.4M
Dividend Yield —
Revenue Growth -22.6% ↘
Op. Margin 30.0% ↗
ROIC 4.1% ↗
FCF / Share $1.65 ↗
Trailing P/E 48.7x
Price / Book 2.0x
FCF Yield 3.7%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$78.70M
↓ -22.6% —
Net Income Profit after all expenses
$8.65M
↓ -85.5% —
Operating Margin Operating profit as % of sales
30.0%
↑ +48.2% 95th
FCF / Share Free cash flow per share
$1.65
↑ +1017.1% —
Long-Term Debt Long-term obligations
$45.00M
↓ -14.3% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
92
Returns
99
Financial Health ↓
83
Cash Quality
29

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters